Evaluation of the prophylactic effect of magnesium versus placebo in reduction of frequency, severity and duration of migraine headaches in children aging 6-18 years old

Shiraz University of Medical Sciences0 个研究点目标入组 140 人开始时间: 待定最近更新: 2023年2月7日

适应症

试验速览

暂无简介。

•Age from 6 to 18 years old
•Weight less than 90 Kg
•Diagnosed as migraine according to IHSC-3 criteria
•At least 4 migraine attacks in month or 8 days-of-headache during at least 1 month ago

•Coexistence of another type of headache
•Migrainous headache in at least 15 days per month
•Using analgesic medications in at least 15 days per month
•Pregnancy or intention of pregnancy
•History of epilepsy or other neurological comorbidities
•Mental retardation defined as IQ<70
•Dependency or addiction to pharmaceutical or illicit drugs
•Magnesium administration contraindications
•Renal failure
•History of renal stone
•Propranolol administration contraindications
•Cardiac conduction block
•Bradycardia
•History of asthma
•History of hypersensitivity reaction to propranolol
•Diabetes mellitus
•Liver insufficiency
•Myasthenia gravis
•History of using migraine prophylaxis medications in the past month
•History of using magnesium supplements in the past month
•History of psychiatric disorders including depression, mood disorders, anxiety disorders or psychotic disorders
•History of using anti-depressants, anti-psychotics, mood stabilizers or sedatives
•Anticipation of patient's poor medication compliance
•Illiteracy of the patient and family and, inability of filling the diary

发起方